UK biotech firms are continuing to reap the benefits from US listings. On Tuesday Autolus Therapeutics, an early stage biopharma firm backed by Syncona Investments, became the latest UK Biotech firm to raise capital on the US Nasdaq in a $100m transaction. The deal shows the continued advantages for early stage European biotech firms in having a US listing.
